Literature DB >> 24002144

Pain management with a topical lidocaine and tetracaine 7%/7% cream with laser dermatologic procedures.

Joel L Cohen.   

Abstract

Pain is a common patient complaint with dermatologic laser procedures and effective pain management is important for the comfort and satisfaction of patients undergoing these procedures. Many topical anaesthetics are available as options to decrease the pain associated with these procedures, although not all have the same degree of safety. An FDA-approved lidocaine and tetracaine topical anesthetic cream [Pliaglis®, liodocaine and tetracaine 7%/7% cream (LT cream), Galderma Laboratories LP, Fort Worth, TX] is safe and effective when used with common laser therapies such as ablative and nonablative laser resurfacing, laser hair removal, laser treatment of vascular lesions, and laser tattoo removal. LT cream should be considered by dermatologists when choosing a topical anesthetic for laser dermatologic procedures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002144

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

1.  Evaluation of the efficacy and safety of a lidocaine and tetracaine (7%/7%) cream for induction of local dermal anesthesia for facial soft tissue augmentation with hyaluronic Acid.

Authors:  Joel L Cohen; Michael H Gold
Journal:  J Clin Aesthet Dermatol       Date:  2014-10

2.  Muscle relaxation for individuals having tattoos removed through laser treatment: possible effects regarding anxiety and pain.

Authors:  Faye Huang; Wen-Jiun Chou; Tien-Hsing Chen; Ching Chen; Yu-Lian Hsieh; Mian-Yoon Chong; Chi-Fa Hung; Shu-Ching Lin; Hsiu-Huang Tsai; Liang-Jen Wang
Journal:  Lasers Med Sci       Date:  2016-05-16       Impact factor: 3.161

3.  Comparison of Permanent Hair Removal Procedures before Gender-Affirming Vaginoplasty: Why We Should Consider Laser Hair Removal as a First-Line Treatment for Patients Who Meet Criteria.

Authors:  Nance Yuan; Alexandra Terris Feldman; Patrick Chin; Michael Zaliznyak; Susan Rabizadeh; Maurice M Garcia
Journal:  Sex Med       Date:  2022-07-30       Impact factor: 2.523

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.